Single nucleotide polymorphisms and functional analysis of MxA promoter region in multiple sclerosis

Hiroyasu Furuyama1, Susumu Chiba, Tamaki Okabayashi

  • 1Department of Neurology, School of Medicine, Sapporo Medical University, Minami 1-jo Nishi 16-chome, Sapporo 060-8543, Japan. furuyama@sapmed.ac.jp

Abstract

Insights

Genetic variations in the myxovirus resistance protein A (MxA) promoter region are linked to multiple sclerosis (MS) over-expression, suggesting a role in disease pathology and potential therapeutic strategies.

Area of Science:

  • Immunogenetics
  • Neuroimmunology
  • Molecular Virology

Background:

  • Myxovirus resistance protein A (MxA), an interferon-inducible protein, serves as an indirect marker for neutralizing antibodies against interferons in multiple sclerosis (MS).
  • MxA possesses antiviral properties by modulating cellular functions, including the apoptotic pathway, which may be relevant to viral-mediated diseases like MS.

Purpose of the Study:

  • To investigate the genetic and pathological significance of MxA in patients diagnosed with multiple sclerosis (MS).
  • To explore the association between single nucleotide polymorphisms (SNPs) in the MxA promoter region and MS susceptibility or progression.

Main Methods:

  • Genotyping of MxA promoter region single nucleotide polymorphisms (SNPs) was performed in a cohort of 67 MS patients.
  • Functional analysis of identified SNPs was conducted using Luciferase assays with promoter constructs, including patient-derived and mutated variants.

Main Results:

  • A significantly higher frequency of a specific haplotype (-88T and -123A) in the MxA promoter was observed in MS patients, correlating with MxA over-expression.
  • Nucleotide -88 demonstrated a key role in MxA regulation in conjunction with type I interferons, while nucleotide -123 exhibited an independent regulatory role without type I interferons.

Conclusions:

  • Single nucleotide polymorphisms (SNPs) within the MxA promoter region are implicated in the pathophysiology of multiple sclerosis (MS).
  • These genetic findings offer a potential basis for novel therapeutic strategies targeting MxA pathways in MS management.